NCT07904013Not yet recruiting
Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis
Impact of an Immuno-radiomic Signature on Intracranial Treatment Efficacy in Non-small Cell Lung Cancer With Brain Metastases at Diagnosis
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
Non-small cell lung cancer frequently spreads to the brain, and brain metastases are associated with poor prognosis and limited treatment response. This retrospective study will investigate whether quantitative features extracted from brain magnetic resonance imaging (MRI), known as radiomic features, are associated with the immune characteristics of brain metastases assessed by bulk RNA sequencing. The main objective is to identify relationships between MRI-based radiomic signatures and tumor immune profiles. A secondary objective is to determine whether radiomic, transcriptomic, or combined radio-transcriptomic signatures can help predict cerebral progression during immunotherapy. The study hypothesis is that MRI-based radiomic signatures may reflect the immune environment of brain metastases and could provide a non-invasive approach for predicting treatment response.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 38 (estimated)
- First submitted
- 13 Oct 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Lung cancer
- NCT number
- NCT07904013
What you commit to
- Study type: Observational
- Planned participants: 38
- From 1 Dec 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Oncogenic addiction amenable to targeted therapy
Other illness
- Small cell lung cancer
- Resection performed for oligometastatic brain disease
- Medical, psychiatric, or other condition preventing understanding of the study information or completion of the study
Other
- Legal protection measure, including safeguard of justice, guardianship, or curatorship
- Deprivation of liberty by judicial or administrative decision
- Inability to provide consent
Who the study is looking for
- Age 18 years or older
- Advanced or metastatic non-small cell lung cancer not amenable to local treatment
- At least one brain metastasis at diagnosis, surgically resected for symptomatic or high-risk disease and/or for diagnostic purposes
- Indication for first-line treatment with immunotherapy and chemotherapy
- Signed CHU de Bordeaux "one shot" form or receipt of the study information letter without opposition to participation within one month
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Bordeaux, Hôpital Saint-André Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.